Roche【1RO】銘柄情報

Roche Holding AG (1RO) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

( - )

買値

売値

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

1,003,923 €

発行済株式数

795,617,637

配当利回り

9.8 (3.11%)

PER

20.5

1 株当たり利益 (EPS)

16.04

歳入

63.36B

純利益

12.88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

www.roche.com

本社

Basel, Switzerland

設立

1896

Roche Holding AG is listed in the sector of the イタリア証券取引所 with ticker 1RO. The last closing price for Roche was -. Over the last year, Roche shares have traded in a share price range of 0.00 € to 0.00 €.

Roche currently has 795,617,637 shares in issue. Roche has a price to earnings ratio (PE ratio) of 20.50.

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C...

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) The filing...

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform AXELIOS 1 delivers a unique combination of accuracy...

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large...

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer The new VENTANA PTEN...

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer Filing acceptance is based on the phase III Alliance...

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg...

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive...

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions Late-breaking Phase II...

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management Roche introduces the...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

1RO - Frequently Asked Questions (FAQ)

What is the current Roche Holding AG share price?

The current share price of Roche Holding AG is 0.00 €

How many Roche Holding AG shares are in issue?

Roche Holding AG has 795,617,637 shares in issue

What is the 1 year trading range for Roche Holding AG share price?

Roche Holding AG has traded in the range of 0.00 € to 0.00 € during the past year

What is the PE ratio of Roche Holding AG?

The price to earnings ratio of Roche Holding AG is 20.5

What is the cash to sales ratio of Roche Holding AG?

The cash to sales ratio of Roche Holding AG is 4.14

What is the registered address of Roche Holding AG?

The registered address for Roche Holding AG is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holding AG website address?

The website address for Roche Holding AG is www.roche.com

VortexDefender302 4分前

$RITE so we're all on the same page,please post current links/url's to back up your claims concerning $RITE etc.Alot of words posted with no substance does not infer anything. Official SEC filings beat message board noise everytime. $RITE Place $RITE Time 💯💯💪💪💰

RITE

garyhalvo 4分前

cashclan 6分前

They were

Already at 1700-1800 shares they did a 200:1 F/S...

OTCQX seems to be the best direction.

PCGC

garyhalvo 8分前

I’m mid 60’s and still moving around pretty good, maybe just park it in my in my foyer in a few years.

StonkMaster 8分前

I'm sitting comfy at 106,000. Relatively young compared to most here (at least that's the feeling I get, I'm 32). My break even is right around 40 cents so I'm still confident I'll see good returns in the near (haha) future.

NWBO

jaws57 10分前

Have a great one yourself!

D-Mike 11分前

Quire: “a unit of paper quantity”

Choir: “an organized group of singers performing in harmony”

You used a lot of words to soft bash a great presentation.

NWBO

jaws57 11分前

Yes, I am able to see your charts. I havent really used Sharpcharts that much but I can read them.

ysung 11分前

I saw this drink GUTSI at GNC stores NYC !!

VMHG

Bngo 12分前

Ready for Merger, Acquisition, or Up-listed on to the NASDAQ

https://s3.amazonaws.com/b2icontent.irpass.cc/2258/20260630110241_063026.mp3

https://www.marketshost.com/ai-score/us/pick-growth-stocks

2026 = $148.87 Million
2025 = $84.04 Mill

ELTP

Implanting 15分前

Peter Schiff from yesterday. If you don't watch the whole video start at about 36:20 into it when he talks about Independence Day in this country.

What the Founders were doing in 1776 and comparisons to how right now we have a lot of the same things going on as we did 250 years ago. N

FFMGF

GoodGuyBill 16分前

Now that Bosch delivered excellent news regarding the PSM analysis, some are suggesting that MHRA may take time to evaluate the data.

I think it is very likely that the MHRA has already reviewed the data and, at the very least, deemed it creditable BEFORE Bosch presented the data at B

NWBO

ysung 19分前

ZERO Revenue for 1 st quarter 2026 !!!!
Am I missing something ??

VMHG

Sangrebandit 19分前

Some of these shares are difficult to cancel, such as the ones that were issued that are restricted that people paid money for those can't be cancelled as you know. I'm really not sure how they're going to clean this up at this point.
And as we all know, ethan was selling restricted shares at

FUNR

BBANBOB 20分前

HAPPY 250TH 4TH OF JULY TO ALL

I hope we can hold onto this country and it's freedom

sage007 20分前

My first sentence of the presentation being non-event was related to its impact on the stock price. Not its validity of science. The validity of the science was recognized by me much longer than most investors here. That is not what I have ever questioned or debated. You edited my statement to fi

NWBO

Don 21分前

What a crock of crap!

AABB

jxyzobrien 25分前

when a market sells
its often just sector rotation
this produces a fast rebound.
now when all sectors are selling
there is the possibility of a major correction
until the FED stops putting in unlimited funds
this rally contiunues

fed QE till

BBANBOB 28分前

HAPPY 250th 4 th of July to all
May we see another 250 yrs of FREEDOM

RKT

jammy32 31分前

He’s not in a hurry so I don’t think he cares. Million a year. 250 million shares that he can take tax free loans on. 90 million more shares coming his way at 15 cents. 5 million bonus. 5,000 per month spending money on his Benz. Life is good for the Nasrat cabal. My opinion

ELTP

100lbStriper 31分前

If the lengthy qualification process involving Netlist’s Lightning DDR5 products and a major global server OEM is indeed approaching completion, the company could be transitioning from years of investment and validation into the commercial harvesting phase management has been working toward.

NLST

sandor8 33分前

As I , previously, said He knows how to do it, already done several times in his life.
Mr Kraig and us we'll make IT !!!!!
I am fully confident in him and me, I can sense it.
Doubters relax or get out for your own mental health.

KBLB

trunkmonk 34分前

while the debt has gone up 10x, and M2 multiples of that, the 50 year super cycle must finish its course. final price 33k.
and while most everyone just keeps getting poorer, Perot and his decedents keep getting wealthier. they still dominate in DFW, not public companies, but an Empire built b

SILVER

HoldHigh 35分前

I've been by that facility also and it is very large.

TRLV

PennyMillions852 36分前

.003 break is needed, Peanutzz already making wild Claims a .05 looking stupid as that was said before and got us know where, pipe down and crawl before you can walk pumper!!!

TWOH

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Roche Holding AG (1RO)

Roche Holding AG (1RO) 銘柄情報

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Roche Holding AG について

1RO 最新ニュース

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

1RO - Frequently Asked Questions (FAQ)

1RO 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE